LION bioscience and BioCat GmbH Announce Exclusive Distribution Partnership
BioCat to Distribute arrayTAG(TM) and arrayBASE(TM) for German Speaking Region
HEIDELBERG, Germany, July 26 /PRNewswire/ -- BioCat GmbH and LION bioscience AG (Nasdaq: LEON; Neuer Markt: LIO, WKN 504 350) announced today that they have entered into an exclusive distribution partnership for two products of LION -- cDNA clones arrayTAG(TM) and the corresponding annotation database arrayBASE(TM) -- for the German-speaking region. These products for expression profiling provides researchers with a more rapid understanding of the behavior and function of genes. The market for expression analysis solutions is growing rapidly as they permit high-throughput analysis in pharmaceutical and basic research for accelerated and lower-cost delivery of new drugs.
"The distribution partnership with BioCat provides us with the chance to strengthen our position in the German, Swiss and Austrian Life Science research market," said Dr. Daniel Keesman, Vice President of Global Sales and Marketing at LION bioscience. "BioCat has proven success in the Life Science business as a specialized distributor of solutions consisting of reagents and services for Genomics and Proteomics. Since our products complement their portfolio very well, we expect this distribution agreement to be mutually beneficial to both of us."
"Due to LION's expertise in drug discovery and Life Science Informatics, arrayTAG(TM) really addresses the needs of the Life Science industry. BioCat GmbH's expertise in marketing and distribution of products for molecular biology will make arrayTAG(TM) and arrayBASE(TM) more widely available to end users," says Dr. Michael Ehret, Managing Director of BioCat. "As a result of this synergy basic research as well as applied medical research can instantly be provided with these valuable clone collections."
LION's arrayTAG(TM) cDNA clones, launched in January, are specifically developed for microarray applications and allow reliable and reproducible expression analysis results. To date, more than 10,000 unique arrayTAG(TM) clones from each mouse and rat, are available. arrayTAG(TM) for further model organisms for biomedical research are currently in production. LION's annotation database arrayBASE(TM) allows the direct access of well-structured and comprehensive information about every single arrayTAG(TM) clone, accelerating the interpretation of differential gene expression.
About BioCat GmbH:
The goal of BioCat GmbH (http://www.biocat.de) is to catalyze innovation in biosciences. Biocat cooperates with selected partners to provide application-oriented solutions to the German-speaking life science research market in the area of genomics and proteomics. BioCat's customers are research laboratories in academic institutions as well as in the pharmaceutical and biotech industry.
About LION bioscience AG:
LION bioscience (http://www.lionbioscience.com) provides proven information and knowledge management solutions to significantly improve life science R&D performance and productivity. These solutions integrate all R&D disciplines, spanning from genetics to early and late discovery through clinical trials. LION applies these solutions for its internal drug discovery program in the field of nuclear receptors with the goal to out-license specific databases, polymorphism marker panels, and validated targets and leads.
Founded in 1997, LION, together with its consolidated subsidiaries, has more than 465 employees, with headquarters in Heidelberg, Germany, and subsidiaries in Cambridge, UK, Cambridge, MA, USA and San Diego, CA, USA. To date, LION has established partnerships with leading life science companies, including Aventis, Bayer, Boehringer Ingelheim, Celera, DuPont, GlaxoSmithKline, GMD, Janssen, Merck Inc., Nestle, Novartis, Paradigm Genetics, Pharmacia & Upjohn, Roche, Sumitomo Pharmaceuticals and Tripos.
All statements in this press release that are not historical are forward- looking statements within the meaning of the U.S. securities laws. Such statements are based on current expectations that are subject to risks and uncertainties. Actual results may vary materially from those projected because of factors such as uncertainties relating to technologies, product development, or manufacturing, market acceptance, cost or pricing of LION's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, or patent protection and litigation. These and other risk factors are discussed in LION's Registration Statement on Form F-4 declared effective by the SEC on February 9, 2001. LION expressly disclaims any obligation or undertaking to release publicly any updates, revisions or corrections to any forward-looking statements or historical information contained herein.
LION bioscience(R) and i-biology(R) are either registered trademarks of LION bioscience AG in the United States and/or other countries, or LION bioscience AG has pending applications for these trademarks in the United States and/or other countries. The names of actual companies and products mentioned herein may be the trademark of the respective owners. Trega Biosciences, Inc. has a pending trademark application for iDEA(TM) in the United States. Trega(R) is a registered trademark of Trega Biosciences, Inc.
For further information please contact:
LION bioscience BioCat GmbH
Dr. Andrea Kreisselmeier Dr. Michael Ehret
Director Corporate Marketing & Communications Managing Director
49-6221-4038-265 +49-6221-5858-44
andrea.kreisselmeier@lionbioscience.com ehret@biocat.de
Noonan/Russo Communications
Ernie Knewitz
1-212-696-4455 ext. 204
ernie.knewitz@noonanrusso.com
MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com
SOURCE LION bioscience AG
CO: LION bioscience AG; BioCat GmbH
ST: Germany
IN: BIO MTC
SU: CON PDT
07/26/2001 01:30 EDT prnewswire.com |
